HK1145806A1 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number
HK1145806A1
HK1145806A1 HK11100032.7A HK11100032A HK1145806A1 HK 1145806 A1 HK1145806 A1 HK 1145806A1 HK 11100032 A HK11100032 A HK 11100032A HK 1145806 A1 HK1145806 A1 HK 1145806A1
Authority
HK
Hong Kong
Prior art keywords
nevirapine
release formulation
extended release
formulation
extended
Prior art date
Application number
HK11100032.7A
Other languages
English (en)
Inventor
Michael L Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1145806(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HK1145806A1 publication Critical patent/HK1145806A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11100032.7A 2007-06-08 2011-01-05 Extended release formulation of nevirapine HK1145806A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
PCT/US2008/065705 WO2008154234A2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine

Publications (1)

Publication Number Publication Date
HK1145806A1 true HK1145806A1 (en) 2011-05-06

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100032.7A HK1145806A1 (en) 2007-06-08 2011-01-05 Extended release formulation of nevirapine

Country Status (29)

Country Link
US (1) US8460704B2 (es)
EP (1) EP2155169B1 (es)
JP (1) JP5417662B2 (es)
KR (1) KR101017862B1 (es)
CN (1) CN101784263B (es)
AR (1) AR066924A1 (es)
AU (1) AU2008262031B2 (es)
BR (1) BRPI0811732A2 (es)
CA (1) CA2687491C (es)
CL (1) CL2008001678A1 (es)
CO (1) CO6150128A2 (es)
DK (1) DK2155169T3 (es)
EA (1) EA018377B1 (es)
EC (1) ECSP099561A (es)
ES (1) ES2574836T3 (es)
HK (1) HK1145806A1 (es)
HU (1) HUE028598T2 (es)
IL (1) IL199924A0 (es)
MA (1) MA31430B1 (es)
MX (1) MX2009007764A (es)
NZ (1) NZ578664A (es)
PE (2) PE20090371A1 (es)
PL (1) PL2155169T3 (es)
TN (1) TN2009000510A1 (es)
TW (1) TWI419716B (es)
UA (1) UA97971C2 (es)
UY (1) UY31128A1 (es)
WO (1) WO2008154234A2 (es)
ZA (1) ZA200904939B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2574836T3 (es) 2007-06-08 2016-06-22 Boehringer Ingelheim International Gmbh Formulación de liberación prolongada de nevirapina
CA2835272A1 (en) 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
CN104023784B (zh) * 2011-08-24 2018-05-25 费斯生物制药公司 供持续释放的活性剂制剂
BR112014021927A2 (pt) * 2012-03-05 2019-09-24 Cipla Ltd composição farmacêutica antirretroviral, processo para preparar uma composição farmacêutica antirretroviral, método para o tratamento ou profilaxia de doenças causadas por retrovírus, e, uso de lamivudina, festinavir e nevirapina
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
WO1999029297A1 (en) * 1997-12-05 1999-06-17 Alza Corporation Osmotic dosage form comprising first and second coats
ATE260642T1 (de) 1998-12-17 2004-03-15 Alza Corp Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
NZ517025A (en) * 1999-09-24 2003-07-25 Janssen Pharmaceutica Nv Antiviral compositions
EP1239840B1 (en) 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20070259014A1 (en) 2003-06-20 2007-11-08 Vgx Pharmaceuticals, Inc. Compositions for and Methods for Treating Hiv
EA008944B1 (ru) 2003-10-01 2007-10-26 Люпин Лимитед Фармацевтическая композиция управляемого высвобождения и способ ее получения
PL1696822T3 (pl) 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
EP1912628A2 (en) 2005-06-29 2008-04-23 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
EP1906937B1 (en) * 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007047371A2 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
ES2574836T3 (es) 2007-06-08 2016-06-22 Boehringer Ingelheim International Gmbh Formulación de liberación prolongada de nevirapina

Also Published As

Publication number Publication date
CA2687491A1 (en) 2008-12-18
NZ578664A (en) 2011-11-25
ECSP099561A (es) 2009-09-29
TWI419716B (zh) 2013-12-21
MA31430B1 (fr) 2010-06-01
DK2155169T3 (en) 2016-06-13
WO2008154234A9 (en) 2009-11-26
WO2008154234A2 (en) 2008-12-18
CL2008001678A1 (es) 2009-09-11
TN2009000510A1 (en) 2011-03-31
EP2155169A2 (en) 2010-02-24
UA97971C2 (ru) 2012-04-10
KR101017862B1 (ko) 2011-03-04
ZA200904939B (en) 2010-04-28
JP2010520891A (ja) 2010-06-17
CN101784263A (zh) 2010-07-21
HUE028598T2 (en) 2016-12-28
AR066924A1 (es) 2009-09-23
JP5417662B2 (ja) 2014-02-19
WO2008154234A3 (en) 2010-01-21
UY31128A1 (es) 2009-01-30
EP2155169B1 (en) 2016-03-23
ES2574836T3 (es) 2016-06-22
PE20131035A1 (es) 2013-10-01
EA200900958A1 (ru) 2010-04-30
US20100278918A1 (en) 2010-11-04
PL2155169T3 (pl) 2016-09-30
US8460704B2 (en) 2013-06-11
CA2687491C (en) 2011-09-20
CO6150128A2 (es) 2010-04-20
KR20100020447A (ko) 2010-02-22
AU2008262031A1 (en) 2008-12-18
AU2008262031B2 (en) 2011-08-25
IL199924A0 (en) 2010-04-15
PE20090371A1 (es) 2009-04-24
MX2009007764A (es) 2009-09-10
EA018377B1 (ru) 2013-07-30
TW200916127A (en) 2009-04-16
CN101784263B (zh) 2012-11-07
BRPI0811732A2 (pt) 2014-11-18

Similar Documents

Publication Publication Date Title
HK1216232A1 (zh) 控釋藥物組合物
IL217153A0 (en) Controlled release formulations
HK1145806A1 (en) Extended release formulation of nevirapine
ZA201004793B (en) Capsule formulation
HK1155712A1 (en) Controlled release of microbiocides
IL201008A0 (en) Modified release dosage forms of tacrolimus
EP2286179A4 (en) Stitching of near-nulled subaperture measurements
EP2318027A4 (en) ISOLATION OF CYCLOPAMINE
GB0907003D0 (en) Formulation
HK1160925A1 (zh) 組織蛋白酶 的用途
EP2296709A4 (en) NIACIN FORMULATIONS WITH MODIFIED RELEASE
GB0822633D0 (en) Formulation
HK1137187A1 (en) Use of tocopherol
EP2413905A4 (en) COMPOSITION
EP2285219A4 (en) CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM
ZA201004772B (en) Novel formulation
EP2291178A4 (en) PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
IL219967A0 (en) Sustained-release formulation
TWI367205B (en) Preparation of paricalcitol
HK1131039A1 (en) Pharmaceutical use of sophoricoside
ZA201004979B (en) Extracts of sclerocarya birrea
GB0814376D0 (en) Formulation
EP2471519A4 (en) CARVEDILOL FORMULATION WITH CONTROLLED RELEASE
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB0914989D0 (en) Drug release formulations